Hong Kong: Venus Medtech raises HK$1.2bn in placement

Hangzhou-based, transcatheter heart valve company Venus Medtech has raised HK$1.2bn (US$153m) in a placement in Hong Kong. The 18.5 million shares priced at the top of the HK$62.88-HK$64.19 range which is a 2% discount to the previous day’s close and a 3.76% discount to the five-day VWAP. The placement represents 9.2% of the company’s enlarged…

You must be a HMI Subscriber to view this content.

Subscribe Now »